Dalpas

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dalpas

Property Description
Active ingredient Buspirone Hydrochloride
Form Tablet (Oral)
Pharmacological class Non-benzodiazepine Anxiolytic (Azapirone)
General purpose Long-term management of persistent anxiety
Origin Synthetic (Prescription-only)

Dalpas is a synthetic, prescription-only medication whose active ingredient is Buspirone Hydrochloride, which is designed for the management of persistent anxiety symptoms. It is a single-ingredient formulation administered in the form of an oral tablet. This drug is categorized as an anxiolytic, and Buspirone belongs to the distinct azapirone chemical class. This classification is a key differentiating factor, signaling that it is chemically and pharmacologically unrelated to traditional sedating compounds like benzodiazepines.

The Unique Profile of a Non-Sedating Anxiolytic

The core purpose of Dalpas is to promote a sustained reduction in symptoms of worry, tension, and restlessness over time. Buspirone is frequently termed anxioselective because it works primarily by modulating brain neurotransmitters, specifically acting on serotonin 5-HT1A receptors, without exerting the significant sedative or muscle-relaxant effects often associated with older anxiety treatments. A distinctive feature of this medication is its lower potential for physical dependence. However, this profile is tied to its characteristic delayed onset of action; clinical findings confirm that the full anti-anxiety benefit typically requires consistent daily use for several weeks, making it unsuitable for acute, immediate relief.

Regulatory References

  1. Buspirone Hydrochloride
  2. oral tablet
  3. anxiolytic
  4. azapirone [FDA]
  5. serotonin 5-HT1A receptors

What side effects are possible with Dalpas?

Possible Side Effects and Safety Information

The official safety profile of Buspirone Hydrochloride (Dalpas) is structured by governmental regulatory authorities to categorize documented adverse reactions by frequency and affected body system.

Adverse effects are generally observed at the beginning of drug therapy and usually subside with continued use, according to official regulatory documentation.


Classification of Adverse Reactions

The most frequently reported adverse reactions are related to the nervous system:

  • Very Common (Affecting 1 in 10 or more): Dizziness and headache are classified as the most frequent reactions.
  • Common (Affecting 1 in 100 to less than 1 in 10): These include somnolence (drowsiness), fatigue, nausea, dry mouth, insomnia, nervousness, and excitement. Common effects are further grouped into Nervous System Disorders and Gastrointestinal Disorders in the regulatory classification framework.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling documents potential serious adverse reactions, although these are typically classified as rare or very rare:

  • Serious Reactions: The risk of Serotonin Syndrome is explicitly noted, particularly when Dalpas is used with other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs). Very rare reports include extrapyramidal disorder (involuntary movements) and convulsions.
  • Contraindications and Impairment: Dalpas is contraindicated for concurrent use with or within 14 days of discontinuing an MAOI. Caution is required for patients with hepatic impairment (liver problems) or renal impairment (kidney problems), as drug concentrations can increase significantly in these populations, as noted by the FDA and SmPC documents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation strictly outlines the expected manifestations of a Dalpas (Buspirone Hydrochloride) overdose and the necessary emergency procedures.

Documented Overdose Signs Required Emergency Actions
Nausea, vomiting, and gastric distress Seek immediate emergency medical help for suspected overdose.
Dizziness and severe drowsiness General symptomatic and supportive measures must be used.
Miosis (pinpoint pupils) Immediate gastric lavage may be performed by medical professionals.

Overdosage with Dalpas alone is stated to typically result in complete recovery. However, urgent medical attention is always required because severe or fatal outcomes have been invariably associated with the co-ingestion of multiple drugs and/or alcohol. Due to the potential for critical risks related to polydrug exposure, individuals experiencing these presentations must contact emergency services immediately.

Because no specific antidote is known for Dalpas, the focus of regulatory-mandated management is continuous supportive care. Official instructions mandate continuous monitoring of key vital functions, specifically respiration, pulse, and blood pressure. The official profile is designed to guide immediate action, acknowledging the favorable outcome when the drug is ingested alone while addressing the critical risks related to co-ingested substances. The regulatory data notes that the dialyzability of the medication has not been determined.

Therapeutic Uses of Dalpas

What Dalpas Treats: Main Uses and Benefits

Managing Chronic Generalized Anxiety Disorder (GAD)

The primary therapeutic purpose of Dalpas is to support the management of persistent anxiety, specifically targeting conditions characterized by periods of heightened symptoms. Dalpas (Buspirone Hydrochloride) is indicated for the management of anxiety disorders or the short-term relief of anxiety symptoms.

Relieving Cognitive and Physical Symptoms

The medication is commonly used to help with symptom clusters that may become intense or disruptive, helping to ease the distress of both excessive, pervasive worry and the physical manifestations of anxiety, such as motor tension and restlessness. This includes supporting symptomatic management in situations involving recurrent manifestations like Generalized Anxiety Disorder (GAD), and when anxiety coexists with depressive symptoms (adjunctive support).

“This non-sedating profile supports alertness, which assists with maintaining daily functional stability.”

Dalpas provides support that helps ease the overall symptom burden, contributing to improved comfort. It is commonly used in situations where patients are seeking options that support a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Cognitive and Physical Tension Dalpas is applied in addressing symptom clusters that interfere with daily comfort, helping to ease the distress of both cognitive and physical tension.

Eligibility and Restrictions for Use

Eligibility Scope

Classification Status According to Regulatory Documents
Populations Allowed Adults 18 years and older. Older adults have a similar efficacy profile to younger adults, but increased sensitivity cannot be ruled out.
Populations Not Recommended Pediatric patients (under 18 years); individuals with severe hepatic impairment; individuals with severe renal impairment; nursing women.
Populations Contraindicated Patients with known hypersensitivity to the drug; patients concurrently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of its discontinuation.

Age- and Condition-Specific Eligibility

  • Pediatric Eligibility: Safety and effectiveness have not been established in patients under 18 years of age. Use in this population is not recommended.
  • Organ Function Status: Administration cannot be recommended in patients with severe hepatic or severe renal impairment. Conditional use and caution are advised for individuals with mild to moderate impairment.
  • Maternal Status: Use during pregnancy is advised only if clearly needed. Administration during lactation should be avoided if clinically possible.

Official Eligibility Statements

Official regulatory documents define non-eligibility through absolute contraindications related to co-medication (MAOIs) and drug allergy status. The eligibility profile also sets age limits, stating effectiveness is not established for the pediatric population. Further conditional restrictions apply to individuals with severe organ impairment where administration is not recommended due to potential changes in drug clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal prohibition documented in regulatory labels due to the risk of severe blood pressure increase or acute serotonergic effects. This mandates a 14-day separation period (washout) when discontinuing an MAOI before initiating Dalpas, or vice versa, as an absolute constraint.

Pharmacokinetic Exposure Modification

The interaction profile is heavily defined by the drug's metabolism via the CYP3A4 enzyme. Strong CYP3A4 inhibitors, such as certain antibiotics (e.g., erythromycin) or antifungals (e.g., ketoconazole), are documented to reduce clearance, leading to an increase in Dalpas plasma concentrations and overall exposure. Conversely, strong CYP3A4 inducers (e.g., rifampin) are documented to accelerate metabolism, resulting in decreased Dalpas plasma concentrations.

Pharmacodynamic and Substance Interactions

Combining Dalpas with other Serotonergic Agents (e.g., SSRIs, SNRIs, triptans) carries the documented risk of developing Serotonin Syndrome due to additive effects. Furthermore, a formal drug-food interaction exists with Grapefruit Juice, which increases Dalpas exposure via CYP3A4 inhibition. Regulatory labels also advise against concurrent use of Alcohol due to the potential for additive central nervous system effects. The risk of exposure-altering interactions is noted to be more clinically significant in patients with hepatic or renal impairment.

Mechanism of Action

How Dalpas Works: Mechanism of Action

The mechanism of action for Buspirone (Dalpas) is based on the gradual, sustained modulation of brain neurotransmitter systems.


Targeted Serotonin 5- HT1A Receptor Modulation

The drug acts primarily as a partial agonist at the brain's 5- HT1A serotonin receptors, influencing the release and activity of serotonin in brain areas associated with limbic system function. This molecular action engages mechanisms that alter activity within these pathways.


Time-Dependent Neural Adaptation and Regulation

The full physiological effect is achieved through a slow, adaptive process: the 5- HT1A partial agonism leads to the desensitization and downregulation of presynaptic autoreceptors over several weeks. This modifies early molecular steps that shape systemic physiological outcomes, resulting in a sustained change in activity within targeted neural pathways, which ultimately contributes to altering overall neuronal excitability.


Anxioselective Physiological Effect Profile

Unlike mechanisms that potentiate GABA at the GABAA receptor, Dalpas's action is anxioselective, focusing on key serotonergic pathways. This engagement of mechanisms results in a physiological profile without significant GABAA-mediated sedation or muscle-relaxing effects. The mechanism's action is confined to sustained, long-term pathway modulation, rather than rapid-onset receptor interaction.

Dosage and Administration Information

How to Use Dalpas: Administration Guidelines

Dalpas (Buspirone Hydrochloride) is administered exclusively via the oral route using a tablet formulation. The usage protocol emphasizes a structured dosing regimen and strict consistency during intake to manage bioavailability and achieve therapeutic stability.

Dosing and Frequency

Treatment is typically initiated at 7.5 mg twice daily (15 mg total per day). The dose is then gradually increased by 5 mg per day at intervals of two to three days. The usual daily dose ranges from 20 mg to 30 mg, given in divided doses, with a maximum recommended total daily intake of 60 mg. The tablet is scored to facilitate accurate fractional dosing during titration.

Administration Conditions and Adjustments

For proper administration, the medicine must be taken in a consistent relationship with food—either always with food or always without food—to ensure steady drug absorption. It is standard practice to avoid consuming grapefruit or grapefruit juice, as this can increase drug plasma concentrations. If a dose is missed, it should be skipped if it is close to the next scheduled time; double dosing is strictly prohibited.

It is recommended that treatment be periodically reassessed if continued for extended periods. A lower dosage may be necessary for patients with existing hepatic or severe renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dalpas

The clinical evaluation of Dalpas (Buspirone) is detailed in official research reports, primarily consisting of randomized, controlled trials (RCTs) and systematic reviews that informed the decisions of regulatory bodies. The evidence base focuses heavily on adult outpatients with persistent anxiety symptoms. The findings described here reflect patterns observed in regulatory-cited studies, providing context on how symptoms were measured and what populations were included.

Evidence for the Management of Generalized Anxiety Disorder (GAD)

Research exploring how symptoms change over time in adults with GAD was reviewed for the medicine's primary indication. This research included a series of short-term, placebo-controlled RCTs, comparing the medicine against both an inactive placebo compound and against other existing anxiety medications. The studies monitored changes measured during the defined study period, with findings describing patterns observed on rating scales that assess components like worry, tension, and other related physical and cognitive symptoms. Research provides insight into short-term changes, but it is important to note that the data show patterns related to a delayed onset of action, meaning the drug was not studied for the acute or immediate relief of symptoms.

Outcomes Measured in Clinical Studies

The clinical trials used standardized rating instruments to monitor symptom intensity. The main tool employed was the Hamilton Rating Scale for Anxiety (HAM-A), which is used to score symptom intensity across categories including physical discomfort and phases of heightened symptom activity. Clinical studies also used clinician-rated Global Impression (CGI) scales, which are designed to help contextualize how physicians reported their overall observation of a patient’s experience.

Evidence in Patients with Coexisting Depressive Symptoms

Studies also explored the use of Dalpas in contexts where patients with GAD reported coexisting, mild depressive symptoms. This included subgroup analyses within the main GAD randomized trials and specialized studies focusing on this population. The studies monitored both anxiety and depressive scores using rating scales for each set of symptoms. Findings described research where the medicine was studied for anxiety symptoms even in the presence of coexisting mild depressive symptoms.

Long-Term Studies and Follow-up Duration

While initial, controlled trials evaluating symptom changes were typically conducted over periods of 3 to 4 weeks, this research focused on episodes where symptoms became more noticeable and provided context on short-term symptom changes. To explore sustained use, Dalpas was also observed in long-term, non-controlled settings, with some research documenting patient responses for up to 12 months.

Key Areas of Research Uncertainty and Gaps

The evidence highlights what is known and what is still uncertain about Dalpas, reflecting that research does not determine whether an individual will respond similarly. The central limitation noted in the research record is the limited controlled evidence for long-term outcomes. Outcomes of use beyond 3 to 4 weeks were not established in controlled trials, meaning the long-term effects are not fully established using the highest quality of evidence. Data for certain groups, such as children and adolescents, remain limited, with certainty remaining low in those specific contexts.

Key Studies & References

  1. An evidence-based approach to treating pediatric anxiety disorders (Includes review of two buspirone RCTs in youth)

Frequently Asked Questions (FAQ)

Common questions about Dalpas (FAQ)

Q: How long does it usually take to notice any effect from Dalpas?

Official product information indicates that Dalpas has a delayed onset of action. The full therapeutic effect typically requires several weeks of consistent use to manifest, rather than being immediate. This period is often described in studies as three to four weeks.


Q: Can Dalpas be used by older adults?

Dalpas is used by adults 18 years and older, including older adults. According to official documents, the efficacy profile in this population is similar to that in younger adults. However, official documents recommend caution, noting that increased sensitivity to the medication cannot be ruled out in this population.


Q: Does Dalpas interact with common over-the-counter pain relievers?

Regulatory warnings about Dalpas interactions mainly concern medicines that affect the CYP3A4 enzyme or other serotonergic agents. There is no widespread regulatory caution against common, single-ingredient over-the-counter pain relievers. Official information emphasizes the need to review all concurrent medications, including over-the-counter drugs, against documented interaction warnings.


Q: Is it normal to feel a little dizzy when first starting Dalpas?

This can be a commonly reported experience. Official regulatory safety data classifies dizziness as a Very Common adverse reaction, meaning it is observed in many patients. Adverse effects like dizziness are generally observed when starting therapy but often subside with continued use.


Q: Is Dalpas considered an opioid or a habit-forming medicine?

Dalpas is classified as an Azapirone, a chemical class unrelated to opioids or benzodiazepines. The official profile notes it has a low potential for physical dependence, consistent with its classification outside of those older drug classes.


Q: Can Dalpas interact with herbal remedies like St. John's Wort?

Official regulatory documentation advises caution when Dalpas is used with other serotonergic agents (medicines that affect serotonin). Herbal products with similar pharmacological actions, such as St. John’s Wort, should be used with caution due to the potential for additive effects.


Q: Does the time of day I take Dalpas matter?

The official prescribing information emphasizes that you must take Dalpas in a consistent relationship with food—either always with food or always without food—to ensure steady absorption. Since the medication is typically prescribed in divided doses, separating the intake times helps maintain consistent drug levels throughout the day.


Q: Are there any specific warnings for pregnant or breastfeeding individuals regarding Dalpas?

According to official regulatory documents, the use of Dalpas during pregnancy is advised only if clearly needed and the benefit is determined to outweigh the risk. Administration during lactation (breastfeeding) is generally not recommended or should be avoided if clinically possible.


Q: Can Dalpas affect sleep patterns?

Yes, Dalpas may affect sleep patterns. Official safety information lists both insomnia (difficulty sleeping) and somnolence (drowsiness) as Common adverse reactions, meaning they are observed frequently in patients.


Q: Is Dalpas the same as [similar drug name]? What's the difference?

Official documents classify Dalpas as an Azapirone, which gives it a distinct pharmacological profile from older anxiety medications, such as benzodiazepines. It is described as anxioselective, meaning its primary mechanism focuses on specific brain pathways.


Q: Does Dalpas affect mood or energy levels?

Official regulatory reporting lists side effects that may affect energy and mood states. These Common reactions include fatigue and insomnia, as well as feelings of nervousness and excitement.


Q: What is the average duration of a course of Dalpas treatment?

Dalpas is officially indicated for the long-term management of persistent anxiety. Regulatory labeling advises that treatment should be periodically reassessed by a healthcare provider if it is continued for extended periods. No single average duration for treatment is specified in official prescribing information.


Q: Is Dalpas known to cause weight gain or loss?

Changes in body weight are not listed among the common side effects of Dalpas. Official clinical trials documented that changes in weight, including both weight gain and weight loss, were reported as infrequent side effects, occurring in less than one percent of participants.


Q: Are there common long-term side effects associated with Dalpas?

Controlled trials establishing effectiveness beyond the initial three to four weeks are limited. However, some long-term observational studies have noted that patients treated for periods up to one year did not report ill effects from the drug.


Q: What is the risk of Dalpas causing stomach issues?

Official safety documentation lists nausea as a Common adverse reaction. Other gastrointestinal symptoms, including diarrhoea, are also reported in the regulatory documentation but occur less frequently.


Q: Can Dalpas be taken with vitamins or supplements?

Regulatory interaction checkers typically find no formal interactions between Dalpas and common multivitamin or mineral supplements. However, caution is advised regarding supplements, and any supplement known to act as a serotonergic agent should be avoided due to the potential for additive effects.


Q: Can people with [specific chronic condition, e.g., diabetes] take Dalpas?

Official labeling lists formal contraindications related to MAOI use and severe liver or kidney impairment, but not specific chronic conditions like diabetes. However, official sources emphasize that any co-existing chronic conditions should be discussed before use.


Q: What is Dalpas approved for in different countries?

Dalpas is approved by regulatory bodies worldwide for the symptomatic treatment of Generalized Anxiety Disorder (GAD) or other persistent anxiety states of clinically relevant severity. This indication is consistent across major regulatory documents, including the FDA and the EMA.


Q: How do I know if Dalpas is working for the intended purpose?

Official research monitored patient responses using standardized rating scales, such as the Hamilton Rating Scale for Anxiety (HAM-A). Patients should be mindful that the gradual onset means initial changes in symptoms of worry and irritability may only be observed after several weeks of consistent use.


Q: Is Dalpas a new medication, or has it been around for a while?

Dalpas, which contains the active ingredient Buspirone, is an established medication with a history of use. The original branded version is no longer on the market, but the medicine is widely available today as a generic alternative.


Q: Does Dalpas require any special blood tests or monitoring?

Routine special blood tests are generally not required for healthy adults using Dalpas. However, official documents specify that close monitoring is often advised for patients with existing hepatic (liver) or severe renal (kidney) impairment due to the risk of altered drug concentrations.


Q: Why do doctors recommend Dalpas over other treatment options?

Official data highlights the drug's distinct pharmacological profile compared to older anxiety medications. It is described as anxioselective and is associated with a low potential for physical dependence and withdrawal. Its mechanism does not carry the significant sedative effects seen with benzodiazepines.


Q: Can men and women use Dalpas for the same conditions?

Official regulatory labels define eligibility for Dalpas based on age and organ function status. There are no distinctions based on gender regarding the primary indication for the management of persistent anxiety in adults.


Q: Are there any reported issues with driving while taking Dalpas?

Official regulatory labeling advises caution regarding activities like driving or operating potentially dangerous machinery. This is because side effects such as dizziness and drowsiness are listed as common. Patients are advised not to drive or operate machinery until they understand the medication's full effect.


Q: Is Dalpas available as a generic medicine?

Yes, the active ingredient in Dalpas, Buspirone, is widely available as a generic alternative. The original branded version of the medication has been discontinued from the market.


Q: What happens if I suddenly stop using Dalpas?

Abrupt discontinuation of Dalpas is not recommended. Official guidance cautions against abrupt cessation. The proper way to discontinue the medicine involves a gradual reduction to avoid the return of anxiety symptoms or the emergence of physical symptoms.


Q: Are the side effects of Dalpas the same for everyone?

No. Official safety data categorizes adverse effects by their frequency, such as Very Common or Common. This indicates that while certain effects are observed often, not every individual will experience every reported side effect, and individual responses can vary.


Q: Does Dalpas interfere with birth control or hormone therapy?

Regulatory interaction checkers generally indicate no formal interactions between the active ingredient, Buspirone, and common combination oral contraceptives. However, official documents emphasize the need to review all concurrent medications and hormone therapies with a professional.


Q: Is there a link between Dalpas and changes in appetite?

Changes in appetite are listed in regulatory documentation as an infrequent or rare side effect. For example, some studies noted that an increased appetite was reported in less than one percent of participants.


Q: How does Dalpas differ from a natural remedy for the same purpose?

Dalpas is a synthetic, prescription-only medication belonging to the Azapirone class. Its action is based on the targeted and documented modulation of serotonin receptors in the brain, which is the mechanism defined in official pharmacological documents.


Q: What is the documented success rate mentioned in the research for Dalpas?

Official clinical trials focused on statistically significant reductions in anxiety scores compared to an inactive placebo. For instance, some research indicated a statistically significant greater reduction in anxiety scale scores compared to placebo in the studied population.


Q: Can Dalpas cause allergic reactions, and what are the signs?

Yes. Known hypersensitivity (severe allergy) to the drug is an official contraindication. As described in regulatory patient information, signs of a severe allergic reaction may include difficulty breathing, wheezing, swelling of the face, or hives.


Q: Are there studies comparing Dalpas to lifestyle changes?

Official regulatory evidence summaries show that clinical trials primarily compared Dalpas against an inactive placebo and against other existing anxiety medications. The published research does not specifically detail comparisons to lifestyle changes alone.


Q: Is Dalpas prescribed for short-term or long-term conditions?

Dalpas is officially indicated for the long-term management of persistent anxiety symptoms. Due to its mechanism of action, which involves a delayed onset, the drug is not considered suitable for the acute or immediate relief of symptoms.


Q: Why might a doctor switch me from a different medicine to Dalpas?

Dalpas is an alternative to older classes of anxiety medications. Its unique profile includes a low potential for physical dependence and an anxioselective mechanism of action that avoids the significant sedative effects seen with other drug classes.


Q: Can Dalpas be used alongside blood pressure medication?

Official labels note caution is required regarding interactions that can affect blood pressure, such as the prohibition of use with MAOIs (Monoamine Oxidase Inhibitors). There are also rare reports of changes in blood pressure during general use.


Q: What are the most commonly reported reasons for stopping Dalpas?

Official reports suggest that reasons for stopping Dalpas include the development of adverse side effects or an individual’s desire to avoid potential rebound symptoms. It is advised to gradually reduce the medication rather than stopping abruptly.


Q: What research is currently being conducted on new uses for Dalpas?

Government-sponsored clinical trial registries, such as ClinicalTrials.gov, indicate that studies are active or have recently concluded exploring the use of Dalpas in other contexts. This has included research into new populations, such as children with Autistic Disorder.


Q: What kind of studies have been done on Dalpas?

The official evidence base for Dalpas consists primarily of randomized, controlled trials (RCTs) conducted in adult outpatients diagnosed with Generalized Anxiety Disorder (GAD). These studies compared the drug against both an inactive placebo and other existing anxiety medications, and also included long-term observation periods.

How should Dalpas be stored and disposed of?

How to Store and Dispose of Dalpas (Buspirone Hydrochloride)

The storage and disposal of Dalpas must strictly follow the requirements documented in official regulatory labeling.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature, specifically between mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F). Excursions outside this range are generally permitted up to mathbf30 C.
  • Protection: The medicine must be kept in a tight, light-resistant container to protect its stability from both moisture and light.
  • Safety: As required for all medicines, Dalpas must be kept mathbfout mathbfof mathbfthe mathbfsight mathbfand mathbfreach mathbfof mathbfchildren.

Official Disposal Guidance

To discard unused or expired Dalpas, disposal is mathbfpreferred through a mathbfdrug mathbftake-back mathbfprogram. The product must not be flushed down the toilet or poured down a sink. If household disposal is the only option, the tablets must be mixed with an mathbfunappealing mathbfsubstance (like used coffee grounds or dirt) and sealed in a container before being placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dalpas found in:

A-Z Index: